Dengue Literature Review

Autoimmunity in Dengue

35 min read

Autoimmunity in Dengue

Overview

Dengue virus infection can trigger transient or prolonged autoimmune responses. Proposed mechanisms include molecular mimicry (cross-reactive antibodies targeting host proteins such as endothelial cells or plasminogen), immune complex (IC) deposition driving tissue inflammation, and persistent Fc receptor-mediated cytokine release. Reported autoimmune sequelae include Guillain-Barré syndrome, retinal vasculitis, IC deposition, and — as a broader syndrome — persistent musculoskeletal and neurological symptoms following acute infection (see Post-Dengue Syndrome). The broader mechanistic framework — including bystander activation and epitope spreading — applies to dengue as it does to other viral infections (see Infection-Triggered Autoimmunity).

Key Points from Literature

ANA in Acute Dengue — Direct HEp-2 Measurement

Chatterjee2024 - ANA Detection in Dengue Kolkata provides the first ANA measurement during acute dengue using the HEp-2 gold standard IIFA (Kolkata, India; n=135 dengue-confirmed, 126 controls):

  • 54.8% of dengue-positive patients ANA-positive by IIFA vs. 10.3% controls (p < 0.001)

  • 18.5% by LIA (18 specific autoantibodies) vs. 7.1% controls (p = 0.009)

  • The ~3:1 IIFA:LIA ratio reveals that the majority of dengue-associated ANAs are non-specific and do not correspond to established autoimmune disease specificities. A polyreactive IgM interpretation: Zhou2007 - Polyreactive Antibodies Natural Antibody Function provides a mechanism — the ~66% IIFA-positive, LIA-negative fraction is consistent with expansion or unmasking of normal germline-encoded polyreactive IgM, which binds structurally unrelated self-antigens (including nuclear antigens) as a constitutive property of the immune repertoire (see Polyreactive Antibodies). Dengue’s inflammatory milieu could amplify the polyreactive IgM background without invoking antigen-specific autoimmune induction — explaining the non-specific IIFA signal, IgM dominance, LIA-negativity, and expected transience (polyreactive IgM half-life ~8h). This applies specifically to the non-specific fraction; the LIA-positive fraction requires separate explanation (molecular mimicry, epitope spreading).

  • Of 7 autoimmune disease categories tested (SLE, Sjögren’s, CREST, MCTD, PBC, myositis, non-rheumatic diseases), only MCTD (multivariate p = 0.041) and autoimmune myositis (multivariate p = 0.018) were significantly elevated in dengue patients — important caveat: wide confidence intervals (OR 14.01, 95% CI 2.197–89.215 and OR 18.37, 95% CI 2.746–122.944 respectively) and a small sample (n=135) make these hypothesis-generating rather than confirmed findings

  • Among symptomatic patients followed 2 years post-infection, 76.9% (20/26) showed ≥1 autoimmune marker alteration, including elevated IC and CRP in 42.3% each and ANA positivity in 23.1% (see Garcia2009 - Long-term Clinical Symptoms Post-Dengue).

  • Elevated IC correlated with higher anti-dengue IgG titers (p = 0.042), consistent with ongoing antibody production driving IC formation.

  • Elevated CRP suggests immune-mediated (non-degenerative) tissue damage; proposed mediators include IL-6, IL-1, IFN-α/β/γ, and TNF, released via persistent FcγRIIa activation by IC in neutrophils, macrophages, and dendritic cells.

  • The FcγRIIa-HH genotype links impaired IC clearance to autoimmune symptoms: failure to clear IC may cause accumulation in tissues or circulation, triggering inflammatory pain and systemic symptoms (see FcγRIIa Receptor).

ANA Positivity in the Context of Viral Infections

Berlin2007 - Autoantibodies in Nonautoimmune Individuals during Infections provides a direct comparator: ANA positivity was 21.7% during acute viral infections (HAV, HBV, HCV; ELISA ANA 8 Pro at 1:100; P<0.013 vs. controls) vs. 3.8% in healthy blood donor controls. This is strikingly similar to Garcia2009’s 23.1% post-dengue finding. Key interpretive distinction: Berlin2007 measured ANA during the acute infection phase, whereas Garcia2009 measured 2 years post-infection — persistence at 2 years is more clinically significant than transient acute-phase elevations.

Evidence from the same literature suggests infection-triggered ANA can be transient: Codes2002 - Autoantibodies in Acute Viral Hepatitis found ANA in 20.5% of acute viral hepatitis patients (IIF ≥1:40, n=156 prospective, Salvador Brazil), falling to 6.4% in convalescence. Whether dengue-associated ANA similarly resolves post-infection, or persists due to mechanisms such as ongoing immune complex formation (elevated IC in Garcia2009 correlating with anti-dengue IgG titers), is a key open question.

The three mechanisms by which infections trigger autoimmunity — molecular mimicry, bystander activation, and epitope spreading — are reviewed in Johnson2022 - Infectious Diseases Autoantibodies and Autoimmunity. For dengue specifically, molecular mimicry (dengue NS1 cross-reactivity with endothelial and platelet proteins) and FcγRIIa-mediated IC clearance failure (see FcγRIIa Receptor) are the most directly evidenced mechanisms.

NS1 Molecular Mimicry — Mechanism and Targets

The NCKU group (Lin, Lei et al.) has provided the most detailed experimental evidence for dengue-specific molecular mimicry. Anti-NS1 antibodies cross-react with platelet and endothelial cell surface proteins, causing immune-mediated platelet destruction (thrombocytopenia) and vascular leakage (haemorrhagic syndrome). Key established points:

  • Anti-platelet and anti-endothelial autoantibody levels are higher in DHF/DSS than DF; absorption with NS1 antigen confirms anti-NS1 accounts for cross-reactivity (see Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection)
  • Specific host proteins cross-targeted: PDI (protein disulfide isomerase), vimentin, ATP synthase β-chain, and HSP60; the responsible NS1 domain is the C-terminal region (aa 311–352) — deletion abolishes cross-reactivity (see Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis); the PDI-specific epitope is further refined to P311–330 (aa 311–330): anti-PDI correlates with anti-P311–330 (r = 0.732 IgG P < 0.0001), and anti-P311–330 is higher in DHF than in DF; HSP60 uses a distinct, unidentified NS1 epitope (see Cheng2015 - NS1 P311-330 Anti-PDI Autoantibodies in DHF, n=43 DHF sera, Vietnam/Taiwan)
  • Anti-NS1 causes endothelial apoptosis (via NO/p53/Bax/caspase-3 pathway) and inflammatory activation (NF-κB → IL-6, IL-8, MCP-1; ICAM-1↑) — two distinct endothelial pathology mechanisms (see Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection)
  • The dengue E protein contains a WGNGCG motif (aa 101–106) homologous to coagulation factors XI, X, IX, VII, thrombin, plasminogen, and tPA; anti-E Abs inhibit plasmin activity; this motif is conserved in haemorrhagic flaviviruses (JEV, WNV, YFV) but absent in HCV — consistent with flavivirus haemorrhagic phenotype (see Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis)
  • Dengue autoimmunity is distinctive in occurring during the acute phase of infection (unlike EBV/SLE, C. jejuni/GBS, which manifest post-infectious) — see NS1 Molecular Mimicry in Dengue for full synthesis

This NS1 molecular mimicry mechanism provides a dengue-specific explanation for why dengue-associated ANA may differ from generic viral-infection-triggered ANA: the direct NS1/host-protein cross-reactivity produces demonstrable functional damage (platelet lysis, vascular leakage) rather than merely epiphenomenal autoantibody production.

Autoantibody Kinetics and Temporal Profile

Wan2012 - Autoimmunity in Dengue Pathogenesis — the capstone review from the NCKU group — provides the most explicit characterisation of dengue autoantibody dynamics: titres peak in the acute phase, decline during convalescence, and persist for several months. This is described as “different from chronic virus infection-associated autoimmune disease.” The paper also adds new mimicry targets beyond Lin2006/Lin2011: LYRIC protein (NS1 aa 116–119), RGD structural mimicry in NS1, and capsid (C) protein as a fourth cross-reactive viral protein.

The “intrinsic ADE” hypothesis in Wan2012 links ADE to autoimmunity mechanistically: FcγR-mediated DENV entry suppresses type I IFN and promotes IL-10/Th2 skewing, creating conditions for enhanced autoantibody production alongside high viral loads.

The temporal profile — resolution within months — makes Garcia2009’s 2-year ANA persistence a significant outlier. Possible explanations: (1) FcγRIIa-HH genotype impairs IC clearance, prolonging immune stimulation; (2) ongoing anti-dengue IgG production (correlated with elevated IC in Garcia2009) sustains the autoantibody response beyond the expected window; (3) the Garcia2009 ANA may reflect a population of autoantibodies distinct from anti-NS1 cross-reactive Abs.

Case reports cited in Wan2012 document individual patients progressing from dengue to frank SLE/lupus nephritis and multiple autoimmune features — though Shih2023 shows this is not detectable as a population-level risk. The primary source for the dengue→SLE+lupus nephritis case cited by Wan2012 is Rajadhyaksha2012 - Dengue Evolving into SLE and Lupus Nephritis (see below).

ANA at 6-Month Follow-Up — A New Time Point

Gawali2021 - ANA Prevalence in Seroconverted Dengue Patients provides the first 6-month post-dengue ANA measurement using HEp-2 IIFA (Gwalior, Madhya Pradesh, India; n=120 IgG-positive dengue patients; 22/120 = 18.33% ANA-positive at 1:100 dilution). This sits chronologically between Chatterjee2024 (acute, 54.8%) and Garcia2009 (2 years, 23.1%), consistent with a declining trajectory from the acute peak. The dominant ANA pattern was AC-1 (nuclear homogeneous, 81.81%) — pointing to dsDNA/histone/nucleosome targets, the same specificity class found positively correlated with platelet counts in DHF patients by Vo2020. However, no control group was tested, making it impossible to determine the regional background ANA rate for Central India. The closest available baseline is Li2019 (Chinese >1:100: 14.01%), which reduces the apparent dengue-attributable excess to ~4 percentage points — within the range of sampling variability for n=120.

Contextualising ANA Positivity Against Healthy-Population Baselines

The 23.1% ANA positivity reported in Garcia2009 must be evaluated against contemporary healthy-population reference data:

All comparisons support elevated ANA positivity in post-dengue symptomatic patients, though the exact testing dilution in Garcia2009 is not explicitly stated and the populations differ. Crucially, no contemporaneous healthy control group was tested for ANA in the Garcia2009 study.

The 2019 EULAR/ACR SLE classification criteria (see Aringer2019 - 2019 EULAR ACR SLE Classification Criteria) establish that ANA ≥1:80 at least once is a mandatory entry criterion for SLE classification; however, the low specificity of ANA means that most ANA-positive post-dengue patients do not have SLE — ANA here likely reflects broader non-specific or infection-triggered autoimmune activation.

Population-Level Autoimmune Disease Risk After Dengue

Li2018: Broad Autoimmune Risk Claimed (ICD-Coded Cohort, Taiwan NHIRD)

Li2018 - Increased Risk of Autoimmune Diseases in Dengue used the Taiwan NHIRD to identify 12,506 hospitalised dengue patients (ICD-9 coded, 2000–2010) matched 1:9 to controls, with 3-year follow-up. Key findings:

  • Overall aHR 1.88 (95% CI 1.49–2.37; p<0.001) for any autoimmune disease
  • Most frequent outcome by case count: primary adrenocortical insufficiency (n=19; aHR 2.05)
  • Significant associations (without multiple comparison correction): SLE (aHR 3.50; n=13), ADEM (aHR 3.80; n=9), systemic vasculitis (aHR 3.70; n=4), myasthenia gravis (aHR 5.35; n=4)
  • GBS was NOT significant (aHR 0.97) — a null finding that persists in the stronger Shih2023 study
  • Proposed mechanism: NS1 activates TLR2/6 and TLR4; TLRs expressed on adrenocortical cells, endothelial cells, and chondrocytes → tissue-specific autoimmune pathology. This extends the established NS1-TLR4 pathway (see Guzman2016 - Dengue Infection) to a new organ target (adrenal cortex), though the hypothesis is unvalidated in experimental models.
  • Substantial residual confounding: dengue group 6 years younger (45.1 vs. 51.1 yrs), more male (50.5% vs. 44.5%), and urban (SMD 0.30–0.38 after matching)

Shih2023: Broad Claim Refuted (Lab-Confirmed Cohort, Taiwan NHIRD)

Shih2023 - Autoimmune Disease Risk After Dengue provides the most rigorous epidemiological test using the same NHIRD, but restricted to laboratory-confirmed dengue. Using 63,814 lab-confirmed dengue patients and 255,256 matched controls, followed for a mean of 4.57 years, the study found:

  • Overall autoimmune disease risk marginally elevated (aHR 1.16; P = 0.0002), but clinically small
  • Only ADEM survives Bonferroni correction across 14 specific outcomes (aHR 2.72; P < 0.0001). All other diseases — including SLE, RA, Sjögren’s, GBS, post-infectious arthritis, and MG — non-significant after correction
  • The ADEM risk is entirely acute: 16 dengue patients (0.025%) developed ADEM in the first month vs. 0 controls (HR >9999); excess disappeared after month 1
  • Identified three methodological problems in Li2018: (1) only 51.4% of hospitalised ICD-coded “dengue” patients were actually lab-confirmed — ~half the Li2018 cohort may not have had dengue; (2) no correction for multiple comparisons across 20+ diseases; (3) restriction to hospitalised patients introduces selection bias

Cross-Study Convergences

The comparison between Li2018 and Shih2023 reveals two findings robust enough to survive completely different methodological approaches:

  1. ADEM risk is real and consistent — aHR 3.80 (Li2018) and aHR 2.72 (Shih2023), both significant, with independent case counts from different study populations. Of all specific autoimmune diseases tested across both papers, ADEM is the one finding that holds.
  2. GBS risk is not elevated — aHR 0.97 (Li2018, non-significant) and non-significant in Shih2023. The GBS-dengue association seen in case reports does not reach statistical significance in either population-based study.

Key implication for this wiki’s core research thread: The Garcia2009 and Lin group findings (elevated autoimmune markers, NS1 molecular mimicry) reflect genuine acute-phase biological phenomena — but they do not translate into lasting autoimmune disease at the population level. The dengue-driven autoimmunity is predominantly transient. The one exception — ADEM — is consistent: it is an acute demyelinating response, not a chronic autoimmune disease.

Macrophage Activation Syndrome — ANA-Negative Severe Dengue Autoimmunity

Morel2014 - Autoimmune Response in Children With Dengue (Paraguay; 3 pediatric cases) introduces a clinically important negative finding for the autoimmunity thread: ANA and anti-dsDNA were negative in all three cases, including the two most severe. The most severe presentations (Cases 2 and 3) fulfilled criteria for secondary Macrophage Activation Syndrome (MAS) / HLH, requiring methylprednisolone, yet had no detectable conventional antinuclear autoantibodies. See Macrophage Activation Syndrome in Dengue for full case details and the HLH-2004 diagnostic criteria.

This is the only wiki source with direct ANA measurement in dengue-associated MAS, and its negative result carries mechanistic weight: MAS/HLH is driven by macrophage and CD8+ T cell hyperactivation rather than by autoantibody-mediated B cell pathology. NS1-TLR4 signalling on macrophages (see NS1 Protein) and ADE-mediated FcγR entry amplifying macrophage activation are plausible triggers. The mechanism is categorically different from NS1 molecular mimicry → ANA → endothelial/platelet damage.

The within-series comparison in Morel2014 is also notable: Case 1 (the mildest, self-limiting case) showed the most conventional autoimmune markers (IgM anticardiolipin positive, hypocomplementemia, proteinuria) while being the least severe clinically. Cases 2 and 3 (the most severe, requiring corticosteroids) had no conventional autoantibodies. This inversion does not necessarily contradict the Wan2012 autoantibody-severity correlation (which measured flow cytometric anti-endothelial antibodies, a different assay), but it highlights that the autoimmune marker panel routinely tested (ANA, anti-dsDNA, lupus anticoagulant) cannot distinguish dengue-MAS from other causes of MAS.

Palacios2016 - Autoimmunity in Dengue Literature Review (a letter to the editor responding to Morel2014) adds another MAS case — an adult woman with concurrent nephrotic syndrome (Lai et al. 2012, France), confirming that dengue-MAS is not solely paediatric. Palacios2016 also documents additional dengue-autoimmune clinical forms: SLE+lupus nephritis (Talib 2013, ANA homogeneous + anti-dsDNA positive — the one case with positive ANA in contrast to Morel2014) and retinal vasculitis (Chang 2007, Singapore, via immune complex deposition).

Transient Multi-Autoantibody Syndrome — Case Report With Full Resolution

Jardim2012 - Autoimmune Features DHF Case Report (n=1 case report, Campinas Brazil — not generalizable) provides the clearest single-case illustration in this wiki of dengue producing a broad multi-autoantibody picture that completely resolves, with key features:

  • ANA 1/320, mitotic spindle fluorescent pattern — distinct from the homogeneous/AC-1 nuclear pattern seen in Gawali2021 and the homogeneous 4+ pattern in Rajadhyaksha2012. The mitotic spindle pattern targets centromere/spindle apparatus proteins rather than nuclear DNA/histones, adding a new autoantigen class to the dengue ANA spectrum.
  • ANA negative at follow-up — full resolution, consistent with the transient dengue ANA model. The mitotic spindle pattern may reflect either epitope spreading (dengue-induced apoptosis releasing spindle apparatus antigens) or polyreactive IgM binding (see Zhou2007 - Polyreactive Antibodies Natural Antibody Function).
  • Cryoglobulins positive → negative at follow-up — first documented cryoglobulinemia case in this wiki. Mechanistically consistent with dengue-driven circulating IC formation in secondary infection.
  • Selective C3 depression (0.39 g/L) with C4 normal (0.33 g/L) — unlike Rajadhyaksha2012 (both C3 22 mg/dL and C4 5 mg/dL depleted). The C4-sparing pattern is atypical for classical pathway complement consumption and may indicate alternative or MBL pathway activation.
  • LE cells in pleural fluid — requiring nuclear material, anti-nuclear IgG, complement, and phagocytic function to co-occur.
  • Anti-dsDNA negative throughout — critical distinguishing feature from SLE; no specific nuclear antigen autoantibody confirmed.
  • Secondary infection (both IgM and IgG positive by DuoCassette).

This case contrasts with the SLE cluster cases (Rajadhyaksha2012 - Dengue Evolving into SLE and Lupus Nephritis, Velazqueza2017 - SLE vs Dengue Case Series) precisely because of full resolution: the same ANA-positive, hypocomplementaemic, lupus-like presentation resolved without any persistent autoimmune diagnosis. Within the dengue-autoimmunity spectrum, Jardim2012 represents the “transient trigger” end, Velazqueza2017/Rajadhyaksha2012 the “sustained/unmasking” end. The case cannot determine which mechanism produced the mitotic spindle ANA — substrate type was not specified, and LIA confirmatory testing is not reported.

Pediatric SLE-Dengue Co-presentation — ANA-Positive Cases

Velazqueza2017 - SLE vs Dengue Case Series extends the ANA-positive SLE-dengue cluster beyond the single Talib 2013 case cited in Palacios2016, providing the first directly reported pediatric SLE-dengue case series from Mexico in this wiki (n=2; ages 3 and 6 years; Guadalajara, Jalisco, Mexico; Hospital General de Occidente, Pediatric Rheumatology Service).

Both cases had the complete SLE autoantibody signature at very high titres:

  • ANA 1:1280 by IIFA — Case 1: homogeneous + cytoplasmic pattern; Case 2: fine speckled — far above the 1:80 mandatory SLE entry criterion (see Aringer2019 - 2019 EULAR ACR SLE Classification Criteria)
  • Antinucleosome antibodies in both: 52 U/ml (Case 1) and 258 IU/ml (Case 2) — targeting histone-DNA complexes; a canonical SLE-specific autoantibody distinct from non-specific infection-triggered ANA
  • Anti-dsDNA positive in both (1:10 and 31 IU/ml)
  • Hypocomplementemia (Case 1)

Case 1 (6F, severe dengue + concurrent SLE diagnosis) responded to chloroquine, azathioprine, and prednisone. Case 2 (3F): dengue was the acute presentation; SLE was diagnosed 2 months later — the most temporally direct case of dengue preceding de novo SLE diagnosis in this wiki, though the authors note that “it is not possible to determine the chronology between dengue and SLE.” Case 2 died from pulmonary haemorrhage one week after SLE diagnosis.

Together with the Talib 2013 case (cited via Palacios2016, Singapore), these cases document an ANA-positive SLE cluster within the broader dengue-autoimmune literature. The contrast with Morel2014’s ANA-negative MAS is complete: dengue-associated immune complications span from ANA-negative, macrophage-driven MAS to ANA-positive, antinucleosome-positive SLE. Whether FC receptor polymorphism, complement gene variation, or other host factors determine which path a given dengue patient takes remains unknown.

The antinucleosome specificity (both cases) is notable in the context of Vo2020’s finding that nuclear antigen IgGs (including histone H3/H4 and nucleosome antigens) are positively correlated with platelet counts in DHF — interpreted as consumption via immune complex formation. Whether very high antinucleosome titres in active SLE represent a production-dominant state that overrides the consumption signal, or whether these are mechanistically different populations of anti-nucleosome antibodies, cannot be resolved from n=2 case reports.

Methodological note: n=2 case series — not generalizable. No dengue serotype data. Temporal sequence ambiguous for Case 1 (concurrent diagnosis). Both cases could represent dengue unmasking pre-existing subclinical SLE rather than de novo triggering.

False-Positive Dengue Serology in Pre-Existing SLE — Reverse Diagnostic Hazard

Santosa2012 - Delayed SLE Diagnosis Dengue Serology (Singapore, NUHS; n=1 case report — not generalizable) documents a clinically important reversal of the usual dengue→autoimmunity direction: pre-existing SLE autoantibodies caused false-positive dengue IgM, delaying SLE diagnosis in an endemic setting. A 20-year-old Malay male was initially treated for probable dengue fever based on positive dengue IgM; 3 weeks later he presented with seizures, ANA 1:320, anti-dsDNA, anti-Ro, RF, hypocomplementemia, and thrombocytopenia — SLE with neuropsychiatric involvement. Dengue IgM was now negative, confirming the initial IgM was false-positive.

Mechanism: Polyclonal B-cell activation in SLE generates ~120 autoantibodies with mixed isotype, affinity, and avidity. Low-affinity IgM autoantibodies (exemplified by RF, itself an IgM against IgG Fc) can non-specifically cross-bind dengue IgM test kit antigens. The Panbio Dengue IgM/IgG immunochromatography kit showed 15% false-positive dengue IgM in RF-positive patients (3/20) but 0/10 false-positive in ANA-positive patients — consistent with the low-affinity IgM mechanism (ANA antibodies in established SLE are predominantly affinity-matured IgG, which does not cross-react). Published multi-kit data (Hunsperger et al. 2009) shows flavivirus, malaria, leptospirosis, and RF cross-reactivity can reach 70% false-positive rates in IgM ELISA across kit designs.

This mechanism connects to the existing polyreactive IgM framework in this wiki: the same low-affinity, broadly cross-reactive IgM species that generates non-specific IIFA-positive ANA during dengue (see Chatterjee2024 - ANA Detection in Dengue Kolkata; ~66% IIFA-positive, LIA-negative dengue patients) can, when present at high concentrations in SLE, cross-react with dengue test kit antigens. The extremes of this spectrum are now both documented: dengue-phase IgM causing non-specific nuclear IIFA reactivity, and SLE-phase IgM causing false-positive dengue immunochromatography.

Bidirectional hazard: Immunosuppressive therapy in established SLE can also cause false-negative dengue serology during true dengue infection, complicating the lupus-flare vs. dengue distinction in both directions. For patients with autoantibodies, NS1 antigen (92% sensitivity, 100% specificity within 9 days; non-immunological detection) or RT-PCR (within 5 days; RNA-based) are preferred as primary confirmatory tests.

Practical implication for the autoimmunity thread: In dengue-endemic regions like Singapore, the SLE-dengue diagnostic bidirectionality is a real clinical hazard. All other SLE-dengue cases in this wiki (Velazqueza2017, Rajadhyaksha2012, Morel2014, Palacios2016) document dengue triggering or co-presenting with SLE. Santosa2012 is the only wiki source documenting the reverse direction — SLE antibodies faking dengue.

Biopsy-Confirmed SLE and Lupus Nephritis After Primary DENV-1 — Adult Case

Rajadhyaksha2012 - Dengue Evolving into SLE and Lupus Nephritis (n=1, 22F, Mumbai India; KEM Hospital) provides the primary-source documentation for a case in which primary DENV-1 infection (IgM+/IgG- by ELISA, DENV-1 genotype 1 by RT-PCR) was followed 4 weeks later by frank SLE with biopsy-confirmed Class IV diffuse proliferative glomerulonephritis. Key features:

  • ANA 1:320 homogeneous 4+, anti-dsDNA 1:80 4+, severely low C3 (22 mg/dL) and C4 (5 mg/dL)
  • Anti-cardiolipin IgM 44 MPLU/mL and IgG 12 GPLU/mL — both elevated and persistent at 4 months; adding an antiphospholipid axis not documented in other dengue-SLE cases in this wiki
  • LE cells in ascitic fluid; negative ANCA and RF
  • Responded partially to methylprednisolone pulse + MMF + hydroxychloroquine
  • Authors claim this as the first published case of dengue fever evolving into lupus nephritis

This case extends the dengue-SLE cluster beyond Velazqueza2017 - SLE vs Dengue Case Series and the Talib 2013 case (cited via Palacios2016 - Autoimmunity in Dengue Literature Review) with: (1) shorter dengue→SLE interval (4 weeks vs. 2 months for Velazqueza2017 Case 2); (2) biopsy confirmation of Class IV LN; (3) confirmed primary infection. The fundamental causal ambiguity remains: no autoantibody testing was performed during acute dengue, so whether dengue triggered de novo SLE or unmasked pre-existing subclinical SLE cannot be resolved. The authors favour the latter interpretation.

Evidence weight: n=1 case report — cannot support generalizable mechanistic claims. The anti-cardiolipin persistence (4 months) is unusual compared with the transient IgM aCL seen in dengue without SLE (Morel2014 Case 1), suggesting SLE-driven antiphospholipid antibody production rather than a dengue-specific transient response.

Systematic Autoantibody Profiling — Protein Microarray in Cambodian Children

Vo2020 - Autoantibody Profiling in Dengue provides the first untargeted, high-throughput characterisation of the autoantibody repertoire in dengue, using a 123-antigen protein microarray in Cambodian pediatric patients (n=32 DENV-positive; 11 ASD, 13 DF, 8 DHF; predominantly secondary infection) vs. healthy donors (n=8).

Key findings bearing directly on the autoimmunity thread:

  • 80 IgM and 6 IgG autoantibodies elevated in DENV-infected patients vs. healthy donors, with the total IgM signal significantly higher (p < 0.01). The breadth — 80 IgM targets spanning complement (C5, C8, C9, factor B, factor H, factor P), coagulation (β2GPI), and other self-proteins — is consistent with bystander polyclonal B cell activation generating low-affinity, broadly cross-reactive IgM.

  • Primary infection has significantly higher IgG autoantibodies than secondary infection (p < 0.01; 70 individual IgG autoantibodies elevated in primary vs. secondary). This inversion — primary > secondary for IgG autoantibody load — is not what severity-based predictions would expect and is a mechanistically important observation. The authors interpret it as “leakiness in B cell tolerance mechanisms” during primary infection, where naïve B cells escaping checkpoint deletion differentiate into IgG-secreting plasma cells. In secondary infection, memory-dominated recall responses may compete with and suppress autoreactive clones. Caveat: the primary group was only n=6, all male, all DENV-1.

  • 19 IgG autoantibodies positively correlated with platelet counts in DHF (Spearman r = 0.74–0.83; all p < 0.05). These include complement components (Factor P, C4), coagulation proteins (prothrombin), and — critically for the ANA thread — nuclear antigens: KU (P70/P80) DNA-binding antigen, SmD, SRP54, Sm/RNP, SmD1, histone H3, histone H4, nucleosome antigen, U1-snRNP-C. The positive direction means low autoantibody = low platelet count. This implicates consumption through immune complex formation rather than direct pathogenicity: as DHF worsens, these autoantibodies (and complement factors C4/Factor P) are consumed through immune complex formation, simultaneously depleting the measured autoantibody pool and contributing to complement dysregulation and platelet clearance.

  • No significant difference in total autoantibody load between ASD and DF/DHF patients, reinforcing the Sungnak2025 finding that the overall autoantibody repertoire does not discriminate severity. The pathologically relevant difference may be in specific antibody consumption patterns and immune complex formation rather than overall production.

The nuclear antigen correlation finding is particularly notable given the existing ANA literature in this wiki: KU (P70/P80), SmD, Sm/RNP, histone, and nucleosome antigens are all canonical ANA targets measured by LIA (see Chatterjee2024 - ANA Detection in Dengue Kolkata and Line Immunoassay ANA). The Vo2020 data raises the possibility that dengue-associated nuclear antigen IgGs are consumed rather than amplified in severe disease — which would produce a negative ANA correlation with severity, the opposite of what naive pathogenic models predict.

Indirect Evidence: Sex and Severity as Cross-Outcome Modifiers

Seet2007 - Post-Infectious Fatigue Syndrome in Dengue and the fatigue/PIF meta-analysis Hertanti2024 - Fatigue and Post-Infectious Fatigue in Dengue do not measure autoimmune markers and are not directly about autoimmunity — but together they bear on the shared host-immunological axis across post-dengue outcomes, and the meta-analysis directly recalibrates one figure this wiki had over-weighted:

1. Severity-independence replication: Post-dengue fatigue at 2 months was not significantly associated with DHF vs. DF (Seet2007, p = 0.855). This replicates Garcia2009’s finding that post-dengue autoimmune markers at 2 years were also not significantly predicted by acute severity (p = 0.086). Hertanti2024 adds a third, larger data point: pooled acute-fatigue × DHF was null and internally contradictory (OR 1.29, NS; Ferreira2018 2.31 harmful vs Recker2024 0.75 protective, I²=93.5%). Across independent cohorts, countries, serotypes, and follow-up windows the pattern holds — post-dengue immune sequelae are governed by host-intrinsic factors rather than the degree of viral pathological burden. (Caveat: Hertanti2024’s DHF→PIF pool is borderline-positive at OR 1.80, p=0.042 on 2 studies — a tension to hold open, not a reversal.)

2. Female sex — a shared but modest modifier (corrected): Earlier wiki text framed Seet2007’s female-sex OR of 9.687 as an “outsized” effect. That framing is now corrected. The 9.687 is Seet2007’s own adjusted multivariate estimate with a 95% CI of 1.546–60.684 — a sparse-data artifact whose width (1.5 to 60.7) signals extreme imprecision, not a large reliable effect. Hertanti2024 pools the unadjusted cross-study female→PIF effect across three studies (Seet2007, Perera2023, Abeysena2019) at OR 1.65 (95% CI 1.27–2.14) with I²=0.00 — a modest, precise, zero-heterogeneity effect. (Hertanti2024’s Table 2 even mis-prints Seet’s value as “9.69” against an incompatible CI of 0.78–4.01; the pool is the trustworthy quantity.) Female sex therefore remains a genuine and consistent PIF risk factor — and a mandatory confounder to control in any ANA↔fatigue analysis — but it is a smaller lever than previously stated. The female excess still converges across (a) healthy-population ANA (2–3× higher; see Antinuclear Antibodies), (b) post-dengue autoimmune markers (Garcia2009, 65.7% vs 36.7%), and (c) post-dengue fatigue/PIF — consistent with sex-linked immunological mechanisms (hormonal regulation of FcγR expression, Th1/Th2 balance, B cell tolerance thresholds) as a common thread. But the magnitude of the fatigue arm is now anchored to 1.65, not 9.687.

3. Autoimmunity named as a hypothesized fatigue mechanism — but untested: Hertanti2024 lists autoimmunity as one of four candidate mechanisms for post-viral fatigue (alongside viral persistence, immune dysfunction, and autonomic dysregulation), sketching an estrogen→B-cell-activation→autoantibody→fatigue chain — but explicitly states it “requires further confirmation,” and the meta-analysis measures no ANA and no autoantibodies. So the field’s largest fatigue synthesis leaves the ANA↔fatigue link exactly where this wiki’s primary thread finds it: hypothesized, biologically plausible, and untested.

Contradictions & Debates

  • No asymptomatic control group was tested for autoimmune markers in Garcia2009 - Long-term Clinical Symptoms Post-Dengue, making it uncertain whether these findings are specific to symptomatic sequelae or occur more broadly in dengue-recovered individuals.

  • The appropriate healthy-population comparator for the Garcia2009 ANA finding is uncertain: the dilution used is not clearly stated, the population is Cuban (not US or European), and ANA prevalence has been rising over time (Dinse2022). The most conservative comparison (against the contemporary 16.1% US rate) still shows elevation, but by a smaller margin than earlier estimates suggested.

  • Substrate incompatibility (critical): Garcia2009 used rat liver tissue as the IIF substrate, whereas all healthy-population reference studies in this wiki use HEp-2 cells (see Indirect Immunofluorescence ANA Test). Rat liver is less sensitive — it detects fewer ANA specificities and likely underestimates ANA prevalence relative to HEp-2. This means the 23.1% post-dengue figure is a floor estimate; had HEp-2 been used, the rate would likely be higher. The cross-study comparisons (23.1% vs. 13.8–16.1%) are therefore directionally valid but the gap may be larger than reported.

  • The Berlin2007 viral-infection ANA rate (21.7%) closely matches Garcia2009 (23.1%), raising the question of whether dengue-associated ANA is qualitatively distinct from generic viral-infection-triggered ANA, or a manifestation of the same phenomenon measured at an unusually late (2-year) time point.

  • Johnson2022 documents that bystander polyclonal activation during severe viral infection (COVID-19) does NOT significantly elevate ANA above ICU-level controls, suggesting that cytokine storm alone is insufficient to explain ANA elevation — making dengue-specific mechanisms (molecular mimicry, FcγRIIa-driven IC persistence) the more plausible explanations for the Garcia2009 finding.

  • Discrepant specific autoimmune signals: Shih2023 (Taiwan, n=63,814 lab-confirmed, population-based) found only ADEM significantly elevated after dengue. Chatterjee2024 (India, n=135, hospital-based) found MCTD and myositis significantly elevated. These findings are not necessarily contradictory — different study designs, settings, populations, and outcome definitions — but they cannot be reconciled into a single picture yet. Shih2023 may have lacked statistical power for rare rheumatological outcomes (MCTD and myositis cases would be very few in any cohort). Alternatively, the Chatterjee2024 signal may reflect setting-specific factors (endemic dengue, hospital enrichment of severe/unusual cases).

  • ANA-negative MAS (Morel2014) vs. autoantibody-severity correlation (Wan2012): Wan2012 (cited in Palacios2016) reports that anti-endothelial cell autoantibody levels — measured by flow cytometry — are higher in DHF/DSS than in DF. This implies autoantibody production tracks with dengue severity. Yet Morel2014’s MAS cases, the most severe autoimmune presentations in this wiki, show negative standard ANA and anti-dsDNA. The resolution: these measure different antibody populations. Wan2012’s “autoantibodies” are anti-endothelial cell Abs by flow cytometry; Morel2014 tested standard antinuclear panel. Additionally, MAS/HLH is macrophage/T cell-driven, not autoantibody-driven. The two observations target categorically different immune effector mechanisms. The practical implication: negative ANA does not rule out severe dengue immune complications — it only excludes one mechanism.

  • Unresolved tension: Garcia2009 found elevated ANA, IC, and CRP at 2 years post-dengue (23.1% ANA positivity), yet Shih2023 finds no elevated incidence of clinical autoimmune diseases over a mean 4.57-year follow-up. These findings appear contradictory but may be reconciled: (1) ANA positivity is not equivalent to autoimmune disease — most ANA-positive individuals, especially at low titres, never develop clinical disease; (2) the Garcia2009 autoimmune markers were measured in a highly selected symptomatic subset with multiple prior infections, while Shih2023 covers all dengue patients including mild/asymptomatic; (3) elevated IC and CRP may reflect post-infectious inflammation rather than true autoimmunity. The Garcia2009 autoimmune marker elevations may represent a biologically real phenomenon that nonetheless falls below the threshold for clinical disease in the vast majority of patients.

SLE-Dengue Bidirectional Clinical Confusion (Farias2024)

Farias2024 - Dengue Mimickers (narrative review, expert consensus, Brazil) provides the clinical context in which dengue-autoimmunity interactions are practically encountered:

  • Bidirectional misdiagnosis: SLE has been misdiagnosed as dengue and dengue as SLE in published reports; the shared features are fever, arthralgia, myalgia, rash, thrombocytopenia, lymphopenia, and elevated transaminases — covering the core dengue clinical presentation entirely
  • False-positive dengue serology in SLE/RA: Commercial dengue IgM ELISA kits cross-react with lupus autoantibodies and rheumatoid factor; RT-PCR within the first 5 days is the preferred discriminator; NS1 antigen detection provides 92% sensitivity / 100% specificity within 5 days. This confirms the Santosa2012 finding at a broader clinical level.
  • Anti-DNA and complement as SLE discriminators: Low complement (C3/C4) and elevated anti-dsDNA antibodies may provide clues toward SLE diagnosis in cases of diagnostic uncertainty — though dengue itself can generate transient anti-nuclear antibodies (see ANA sections above)
  • Dengue triggering specific autoimmune conditions: Case reports document dengue triggering necrotizing immune-mediated myopathy (9-year-old, CPK 30,833 mg/dL; juvenile dermatomyositis excluded by absence of rash), and sacroiliitis (unilateral, young woman; coincidental co-occurrence could not be excluded). Li2018 Taiwan cohort data (n=12,506) cited for post-dengue autoimmune risk elevation across multiple conditions.
  • Kawasaki disease (KD) and MIS-C as dengue mimickers: KD in children <5 years is a recognised dengue differential, especially with prolonged fever; oral changes (“strawberry tongue”), finger desquamation, conjunctival injection, and thrombocytosis (vs. thrombocytopenia in dengue) are key differentiators. MIS-C (post-SARS-CoV-2) distinguished from severe dengue by higher CRP, conjunctival injection, and oral mucosal changes; dengue shows higher Hb/Hct, lower platelets, greater aminotransferase elevation.
  • ITP as dengue comorbidity and trigger: Dengue may co-occur with ITP or trigger ITP; isolated thrombocytopenia without lymphopenia/viral syndrome/fever argues for ITP; dengue-ITP fatal case in Brazil (DENV-4) documented

Pemphigus and Acantholysis — Anti-Desmoglein Autoantibodies in Dengue

Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review (narrative review, Kolkata India — secondary source) introduces a dermatological axis of dengue autoimmunity not previously covered in this wiki: anti-desmoglein (DSG) autoantibodies causing pemphigus-like acantholysis and intra-epidermal blister formation.

  • Pemphigus vulgaris (PV): anti-DSG-1 + anti-DSG-3 → mucous membranes + skin involvement
  • Pemphigus foliaceus (PF): anti-DSG-1 only → superficial skin blistering
  • Both have been associated with DHF and DF patients; DENV-infected patients developed epidermal blisters following passive transfer of anti-DSG antibodies to neonatal mice
  • Mechanism: anti-DSG-3 antibodies target the N-terminal extracellular domain 1 (EC1) of DSG-3 → either (1) steric hindrance preventing trans-adhesive DSG-DSG interaction (signalling-independent) or (2) P38 MAPK-dependent DSG-3 clustering and endocytosis → keratin filament collapse → desmosome internalisation → acantholysis
  • The pathogenic mechanism generalises across PV autoantibodies: IgG fractions from PV sera cause blistering; immune adsorption of anti-DSG1/3 eliminates blister-inducing capacity
  • Other viruses (EBV, CMV, HSV-1/2) are also associated with pemphigus; DENV is the latest addition to this list

Epistemic status: Evidence for dengue-pemphigus rests on case reports and passive transfer animal models — not prospective cohort data. Whether dengue generates anti-DSG antibodies through molecular mimicry, bystander activation, or unmasks pre-existing pemphigus susceptibility is not established. Anti-DSG antibodies have not been systematically measured in dengue patient cohorts.

See Pemphigus and Acantholysis in Dengue for full mechanistic detail.

Sources

Graph View

Backlinks